AUPP818099A0 - New n-containing heterocyclic compounds - Google Patents

New n-containing heterocyclic compounds

Info

Publication number
AUPP818099A0
AUPP818099A0 AUPP8180A AUPP818099A AUPP818099A0 AU PP818099 A0 AUPP818099 A0 AU PP818099A0 AU PP8180 A AUPP8180 A AU PP8180A AU PP818099 A AUPP818099 A AU PP818099A AU PP818099 A0 AUPP818099 A0 AU PP818099A0
Authority
AU
Australia
Prior art keywords
new
containing heterocyclic
heterocyclic compounds
compounds
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP8180A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to AUPP8180A priority Critical patent/AUPP818099A0/en
Publication of AUPP818099A0 publication Critical patent/AUPP818099A0/en
Priority to TW088123003A priority patent/TWI229075B/zh
Priority to PCT/JP2000/000017 priority patent/WO2000042011A1/en
Priority to HU0105108A priority patent/HU230422B1/hu
Priority to KR10-2004-7009661A priority patent/KR100520406B1/ko
Priority to ES00900121T priority patent/ES2363492T3/es
Priority to US09/869,962 priority patent/US6710043B1/en
Priority to CNB008027455A priority patent/CN1142910C/zh
Priority to RU2001122727/04A priority patent/RU2208608C2/ru
Priority to BRPI0008753A priority patent/BRPI0008753B8/pt
Priority to KR10-2001-7007314A priority patent/KR100525809B1/ko
Priority to CA002360360A priority patent/CA2360360C/en
Priority to HK02105923.9A priority patent/HK1044337B/zh
Priority to TR2001/02038T priority patent/TR200102038T2/xx
Priority to DE60045759T priority patent/DE60045759D1/de
Priority to CZ20012562A priority patent/CZ20012562A3/cs
Priority to EP00900121A priority patent/EP1140836B1/en
Priority to AT00900121T priority patent/ATE502923T1/de
Priority to AU18904/00A priority patent/AU760434B2/en
Priority to JP2000593579A priority patent/JP3617454B2/ja
Priority to IL14384100A priority patent/IL143841A0/xx
Priority to ARP000100123A priority patent/AR028812A1/es
Priority to ZA200104713A priority patent/ZA200104713B/en
Priority to IL143841A priority patent/IL143841A/en
Priority to JP2003132491A priority patent/JP2004002414A/ja
Priority to US10/618,743 priority patent/US20040014745A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AUPP8180A 1999-01-14 1999-01-14 New n-containing heterocyclic compounds Abandoned AUPP818099A0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds
TW088123003A TWI229075B (en) 1999-01-14 1999-12-27 New amide compounds
IL14384100A IL143841A0 (en) 1999-01-14 2000-01-06 Amide compounds and pharmaceutical compositions containing the same
HK02105923.9A HK1044337B (zh) 1999-01-14 2000-01-06 酰胺化合物
CZ20012562A CZ20012562A3 (cs) 1999-01-14 2000-01-06 Amidové sloučeniny
KR10-2004-7009661A KR100520406B1 (ko) 1999-01-14 2000-01-06 아미드 화합물을 포함하는 약제학적 조성물
ES00900121T ES2363492T3 (es) 1999-01-14 2000-01-06 Compuestos amídicos.
US09/869,962 US6710043B1 (en) 1999-01-14 2000-01-06 Amide compounds
CNB008027455A CN1142910C (zh) 1999-01-14 2000-01-06 酰胺化合物
RU2001122727/04A RU2208608C2 (ru) 1999-01-14 2000-01-06 Амиды кислот, способ их получения и фармацевтическая композиция на их основе
BRPI0008753A BRPI0008753B8 (pt) 1999-01-14 2000-01-06 composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida
KR10-2001-7007314A KR100525809B1 (ko) 1999-01-14 2000-01-06 아미드 화합물
CA002360360A CA2360360C (en) 1999-01-14 2000-01-06 Piperidyl benzamide compounds, composition containing same and their use thereof
PCT/JP2000/000017 WO2000042011A1 (en) 1999-01-14 2000-01-06 Amide compounds
TR2001/02038T TR200102038T2 (tr) 1999-01-14 2000-01-06 Amid bileşenler
DE60045759T DE60045759D1 (de) 1999-01-14 2000-01-06 Amid-verbindungen
HU0105108A HU230422B1 (hu) 1999-01-14 2000-01-06 N-(1-acetilpiperidin-4-il)-4-fluor-benzamid és az azt tartalmazó gyógyszerészeti készítmények
EP00900121A EP1140836B1 (en) 1999-01-14 2000-01-06 Amide compounds
AT00900121T ATE502923T1 (de) 1999-01-14 2000-01-06 Amid-verbindungen
AU18904/00A AU760434B2 (en) 1999-01-14 2000-01-06 Amide compounds
JP2000593579A JP3617454B2 (ja) 1999-01-14 2000-01-06 アミド化合物
ARP000100123A AR028812A1 (es) 1999-01-14 2000-01-12 Compuestos de amida, utiles para potenciar la actividad colinergica; proceso para prepararlos; composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos para preparar dichas composiciones y/o prevenir la amnesia y/o demencia y metodo para tratar dichas enfermedades
ZA200104713A ZA200104713B (en) 1999-01-14 2001-06-08 Amide compounds.
IL143841A IL143841A (en) 1999-01-14 2001-06-19 Amid compounds, processes for their preparation, and pharmaceutical preparations containing them
JP2003132491A JP2004002414A (ja) 1999-01-14 2003-05-12 アミド化合物
US10/618,743 US20040014745A1 (en) 1999-01-14 2003-07-15 Amide compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds

Publications (1)

Publication Number Publication Date
AUPP818099A0 true AUPP818099A0 (en) 1999-02-11

Family

ID=3812385

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPP8180A Abandoned AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds

Country Status (21)

Country Link
US (2) US6710043B1 (https=)
EP (1) EP1140836B1 (https=)
JP (2) JP3617454B2 (https=)
KR (2) KR100525809B1 (https=)
CN (1) CN1142910C (https=)
AR (1) AR028812A1 (https=)
AT (1) ATE502923T1 (https=)
AU (1) AUPP818099A0 (https=)
BR (1) BRPI0008753B8 (https=)
CA (1) CA2360360C (https=)
CZ (1) CZ20012562A3 (https=)
DE (1) DE60045759D1 (https=)
ES (1) ES2363492T3 (https=)
HK (1) HK1044337B (https=)
HU (1) HU230422B1 (https=)
IL (2) IL143841A0 (https=)
RU (1) RU2208608C2 (https=)
TR (1) TR200102038T2 (https=)
TW (1) TWI229075B (https=)
WO (1) WO2000042011A1 (https=)
ZA (1) ZA200104713B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
AU2002224046A1 (en) * 2000-12-07 2002-06-18 Fujisawa Pharmaceutical Co. Ltd. Nootropic effect enhancer
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CN100340167C (zh) * 2002-12-06 2007-10-03 陶氏农业科学公司 增效组合物
WO2005089380A2 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US20050026844A1 (en) * 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JP2008517072A (ja) 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤
JP2008519078A (ja) * 2004-11-04 2008-06-05 ニューロゲン コーポレイション Ｃｂ１拮抗薬としてのアリールアルキル尿素類
EP1940786B1 (en) 2005-09-16 2010-08-18 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
TW200825072A (en) * 2006-10-20 2008-06-16 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
US20080200444A1 (en) * 2006-10-20 2008-08-21 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
KR101486605B1 (ko) 2007-04-20 2015-01-26 센주 세이야꾸 가부시키가이샤 신경돌기 형성 촉진제
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CN101910150B (zh) 2007-11-05 2013-09-18 诺瓦提斯公司 作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物
MX2010006063A (es) 2007-12-03 2010-07-01 Novartis Ag Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (https=) * 1969-06-30 1974-10-28
US3647805A (en) * 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (https=) * 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
DE2860314D1 (en) * 1977-11-24 1981-02-19 Synthelabo Derivatives of naphthalene, process for their preparation and their therapeutic application
DE3544244A1 (de) * 1985-12-14 1987-06-25 Minnesota Mining & Mfg Vorrichtung zum entnehmen von fuellgut aus beuteln
ES2053480T3 (es) * 1986-07-31 1994-08-01 Otsuka Pharma Co Ltd Un procedimiento para preparar un derivado de carboestirilo.
CA1322199C (en) * 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 ４−アミノピリジン誘導体及びその酸付加塩
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5656642A (en) 1993-04-07 1997-08-12 Otsuka Pharmaceutical Co., Ltd. Peripheral vasodilating agent containing piperidine derivative as active ingredient
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
ES2158896T3 (es) * 1993-06-18 2001-09-16 Fujisawa Pharmaceutical Co Nuevo compuesto intermedio para uso en sintesis y procedimiento para producir un derivado de aminopiperazina.
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
DE69628559T2 (de) 1995-04-07 2004-04-29 Schering Corp. Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
US6077857A (en) * 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ZA9710872B (en) * 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
KR20000057303A (ko) * 1996-12-24 2000-09-15 후지야마 아키라 아미노피페라진 유도체의 신규 용도
US6291464B1 (en) * 1997-02-17 2001-09-18 Fujisawa Pharmaceutical Co., Ltd. Aminopiperazine derivatives
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Also Published As

Publication number Publication date
KR100520406B1 (ko) 2005-10-11
CA2360360C (en) 2009-09-08
CN1142910C (zh) 2004-03-24
JP2002534503A (ja) 2002-10-15
HU230422B1 (hu) 2016-05-30
HUP0105108A2 (hu) 2002-05-29
JP2004002414A (ja) 2004-01-08
IL143841A (en) 2006-07-05
US20040014745A1 (en) 2004-01-22
KR20010093819A (ko) 2001-10-29
RU2208608C2 (ru) 2003-07-20
EP1140836B1 (en) 2011-03-23
IL143841A0 (en) 2002-04-21
ES2363492T3 (es) 2011-08-05
BR0008753A (pt) 2001-11-06
BRPI0008753B8 (pt) 2021-05-25
CA2360360A1 (en) 2000-07-20
ZA200104713B (en) 2002-09-09
ATE502923T1 (de) 2011-04-15
CN1336917A (zh) 2002-02-20
KR20040063001A (ko) 2004-07-09
KR100525809B1 (ko) 2005-11-03
CZ20012562A3 (cs) 2001-11-14
DE60045759D1 (de) 2011-05-05
HK1044337A1 (en) 2002-10-18
US6710043B1 (en) 2004-03-23
EP1140836A1 (en) 2001-10-10
HUP0105108A3 (en) 2002-11-28
TWI229075B (en) 2005-03-11
AR028812A1 (es) 2003-05-28
HK1044337B (zh) 2004-11-26
WO2000042011A1 (en) 2000-07-20
BR0008753B1 (pt) 2013-11-12
JP3617454B2 (ja) 2005-02-02
TR200102038T2 (tr) 2002-01-21

Similar Documents

Publication Publication Date Title
AUPP818099A0 (en) New n-containing heterocyclic compounds
GB9929973D0 (en) Heterocyclic compounds
AU1978699A (en) Heterocyclic compounds
AU5413600A (en) Compounds
AU1278701A (en) Novel compounds
AUPP003197A0 (en) New heterocyclic compounds
AU2408300A (en) Novel compounds
AU6032100A (en) New compounds
AU1746401A (en) Compounds
AU2001258841A1 (en) Heterocyclic compounds
AP2002002413A0 (en) Heterocyclic compounds inhibiting angiogenesi
AUPP921299A0 (en) New heterocyclic compounds
AU2356301A (en) Silylated heterocyclic compounds
AU2663100A (en) Substituted aryl heterocyclic compounds
AUPO622597A0 (en) New heterocyclic compounds
AU4132200A (en) Novel compounds
AU2109700A (en) Novel compounds
AU3730699A (en) Heterocyclic compound
AU4156800A (en) Novel compounds
AU2288900A (en) Novel compounds
AU2668000A (en) Bis-styrylbiphenyl compounds
AU5119400A (en) Compounds
AUPR195500A0 (en) N-containing heterocyclic compounds
AUPQ750100A0 (en) N-containing heterocyclic compounds
AU2829100A (en) New heterocyclic compounds